9 ways to improve developmental screening referrals

The American Academy of Pediatrics urges clinicians to offer confidential, adolescent-centered contraceptive care using evidence-based, equity-informed approaches.

Garadacimab-gxii is the only treatment to target factor Xlla for prophylactic use to prevent attacks of HAE in patients aged 12 years and older.

The approval for ustekinumab-stba now offers all dosage forms to the reference product, ustekinumab, and is indicated for patients aged 6 to 17 years.

Research presented at NUTRITION 2025 shows that fathers with improved adolescent diets are more likely to model and monitor healthy eating for their children.